BACKGROUND: To test whether trazodone, one of the most commonly prescribed medications for treatment of insomnia, improves subjective and/or objective sleep among methadone-maintained persons with sleep complaints, we performed a randomized, double-blind, placebo-controlled trial with 6-month follow-up. METHODS: From eight methadone maintenance programs in the northeastern United States, we recruited 137 persons receivingmethadone for at least 1 month who reported a Pittsburgh Sleep Quality Index (PSQI) score of six or higher. Two-night home polysomnography (PSG) was completed at baseline and 1 month later, with morning surveys and urine drug toxicologies. Interviews assessed sleep over the past 30 days at baseline and 1-, 3-, and 6-month follow-ups. RESULTS:Participants averaged 38 years of age, were 47% male, and had a mean PSQI total score of 12.9 (±3.1). At baseline, intervention groups did not significantly differ on 10 PSG-derived objective sleep measures and 11 self-reported measures. Over 88% (n=121) of participants completed the PSG at 1-month. Without adjusting p-values for multiple comparisons, only 1 of 21 sleep measure comparisons was statistically significant (p<.05). The effect of trazodone on mean PSQI scores during the 6-month follow-up was not statistically significant (p=.10). Trazodone neither significantly increased nor decreased illicit drug use relative to placebo. CONCLUSIONS:Trazodone did not improve subjective or objective sleep in methadone-maintained persons with sleep disturbance. Other pharmacologic and non-pharmacologic treatments should be investigated for this population with high rates of insomnia.
RCT Entities:
BACKGROUND: To test whether trazodone, one of the most commonly prescribed medications for treatment of insomnia, improves subjective and/or objective sleep among methadone-maintained persons with sleep complaints, we performed a randomized, double-blind, placebo-controlled trial with 6-month follow-up. METHODS: From eight methadone maintenance programs in the northeastern United States, we recruited 137 persons receiving methadone for at least 1 month who reported a Pittsburgh Sleep Quality Index (PSQI) score of six or higher. Two-night home polysomnography (PSG) was completed at baseline and 1 month later, with morning surveys and urine drug toxicologies. Interviews assessed sleep over the past 30 days at baseline and 1-, 3-, and 6-month follow-ups. RESULTS:Participants averaged 38 years of age, were 47% male, and had a mean PSQI total score of 12.9 (±3.1). At baseline, intervention groups did not significantly differ on 10 PSG-derived objective sleep measures and 11 self-reported measures. Over 88% (n=121) of participants completed the PSG at 1-month. Without adjusting p-values for multiple comparisons, only 1 of 21 sleep measure comparisons was statistically significant (p<.05). The effect of trazodone on mean PSQI scores during the 6-month follow-up was not statistically significant (p=.10). Trazodone neither significantly increased nor decreased illicit drug use relative to placebo. CONCLUSIONS:Trazodone did not improve subjective or objective sleep in methadone-maintained persons with sleep disturbance. Other pharmacologic and non-pharmacologic treatments should be investigated for this population with high rates of insomnia.
Authors: T Hori; Y Sugita; E Koga; S Shirakawa; K Inoue; S Uchida; H Kuwahara; M Kousaka; T Kobayashi; Y Tsuji; M Terashima; K Fukuda; N Fukuda Journal: Psychiatry Clin Neurosci Date: 2001-06 Impact factor: 5.188
Authors: Katherine M Sharkey; Megan E Kurth; Bradley J Anderson; Richard P Corso; Richard P Millman; Michael D Stein Journal: Drug Alcohol Depend Date: 2010-09-17 Impact factor: 4.492
Authors: Nadia Solowij; Robert S Stephens; Roger A Roffman; Thomas Babor; Ronald Kadden; Michael Miller; Kenneth Christiansen; Bonnie McRee; Janice Vendetti Journal: JAMA Date: 2002-03-06 Impact factor: 56.272
Authors: George H Trksak; J Eric Jensen; David T Plante; David M Penetar; Wendy L Tartarini; Melissa A Maywalt; Michael Brendel; Cynthia M Dorsey; Perry F Renshaw; Scott E Lukas Journal: Drug Alcohol Depend Date: 2009-09-22 Impact factor: 4.492
Authors: Katherine M Sharkey; Megan E Kurth; Bradley J Anderson; Richard P Corso; Richard P Millman; Michael D Stein Journal: Drug Alcohol Depend Date: 2010-01-15 Impact factor: 4.492
Authors: Emily E Hartwell; James G Pfeifer; Jenna L McCauley; Megan Moran-Santa Maria; Sudie E Back Journal: Addict Behav Date: 2014-06-02 Impact factor: 3.913
Authors: Jeremiah W Bertz; David H Epstein; David Reamer; William J Kowalczyk; Karran A Phillips; Ashley P Kennedy; Michelle L Jobes; Greg Ward; Barbara A Plitnick; Mariana G Figueiro; Mark S Rea; Kenzie L Preston Journal: J Subst Abuse Treat Date: 2019-08-14
Authors: Hazel Everitt; David S Baldwin; Beth Stuart; Gosia Lipinska; Andrew Mayers; Andrea L Malizia; Christopher Cf Manson; Sue Wilson Journal: Cochrane Database Syst Rev Date: 2018-05-14